公开(公告)号：US10195220B2

公开(公告)日：2019-02-05

申请号：US14771285

申请日：2014-03-03

申请人： Aston University

发明人： Asif Ahmed ,  Keqing Wang

IPC分类号： A61K31/675 ,  A61K31/095

摘要： The application describes Hydrogen Sulphide (H2S), or a (H2S) generating compound or compound capable of stimulating H2S production in a pregnant subject, for use in the treatment of pre-eclampsia (PE) or fetal growth restriction.

公开(公告)号：US11065222B2

公开(公告)日：2021-07-20

申请号：US16516597

申请日：2019-07-19

申请人： Aston University

发明人： Asif Ahmed ,  Keqing Wang ,  Shakil Ahmad

IPC分类号： A61K31/198 ,  G01N33/68

摘要： The invention provides a method of diagnosis or prognosis of preeclampsia in a pregnant subject, comprising providing a sample from a pregnant subject and measuring the ratio between the amount of (a) one or both of sFlt-1 and PlGF, and (b) one or both of a breakdown product of heme and a breakdown product of arginine, in the sample. Also described are assay kits and a computer adapted for use in the method. Also described is a method of treating preeclampsia, comprising administering a pharmaceutically effective amount of L-arginine and/or citrulline and an inhibitor of arginase or pharmaceutically acceptable salts thereof. Also described is a method of treating cancer, comprising treating a subject with a therapeutically effective amount of an anti-VEGF compound, L-arginine and an arginase inhibitor.

公开(公告)号：US10821122B2

公开(公告)日：2020-11-03

申请号：US16229173

申请日：2018-12-21

申请人： Aston University

发明人： Asif Ahmed ,  Keqing Wang

IPC分类号： A61K31/675 ,  A61K31/095

摘要： The application describes Hydrogen Sulphide (H2S), or a (H2S) generating compound or compound capable of stimulating H2S production in a pregnant subject, for use in the treatment of pre-eclampsia (PE) or fetal growth restriction.

公开(公告)号：US10357469B2

公开(公告)日：2019-07-23

申请号：US15551468

申请日：2016-02-18

申请人： Aston University

发明人： Asif Ahmed ,  Keqing Wang ,  Shakil Ahmad

IPC分类号： G01N33/68 ,  A61K31/198

摘要： Described is a method of diagnosis or prognosis of preeclampsia in a pregnant subject, comprising providing a sample from a pregnant subject and measuring the ratio between the amount of (a) one or both of sFlt-1 and PlGF, and (b) one or both of a breakdown product of heme and a breakdown product of arginine, in the sample. Also described are assay kits and a computer adapted for use in the method. Also described is a method of treating preeclampsia, comprising administering a pharmaceutically effective amount of L-arginine and/or citrulline and an inhibitor of arginase or pharmaceutically acceptable salts thereof. Also described is a method of treating cancer, comprising treating a subject with a therapeutically effective amount of an anti-VEGF compound, L-arginine and an arginase inhibitor.